Malaria PK/PD of ivermectin in relation to malaria vector control
Conditions
Interventions
Repeated ivermectin
Single high dose ivermectin
Albendazole
No treatment
Sponsors
University of Oxford
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: i. Male or female 18 - 45 years old; ii. Body weight over 50Kg; iii. Good health or no medical conditions that could interfere with the study according to the opinion of the study clinician; iv. Willingness to participate voluntarily in all study procedures; v. Plans to remain available for study participation within the next 7 months; vi. Use of effective method of contraception documented through a family planning card for the duration of study for female participants; vii. Ability to give informed consent and communicate with the study personnel.
Exclusion criteria
Exclusion criteria: i. Feeling sick or presenting signs of sickness, which are considered by the project physician to not be temporary condition or likely to resolve before pre-enrolment screening; ii. Body weight below 50Kg; iii. Positive for malaria rapid diagnostic test (mRDT); iv. Lactating or pregnant verified through ß-hCG urine test; v. Clinically significant laboratory abnormality as judged by the study clinician; vi. Receiving or having received in the past 30 days treatments that could, in the eyes of the investigator, interfere with the study; vii. Hypersensitivity against any of the study drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mosquito survival up to 28 days post blood feeding will be assessed by measuring the daily proportion of knocked-down mosquitoes after feeding on blood from participants up to 28 days post treatment with either ivermectin 300mcg/Kg x3, single dose ivermectin 400mcg/Kg x1, single dose albendazole 400mg or no treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Ivermectin plasma concentration ng/L | — |
Countries
Kenya
Contacts
Public ContactMarta Maia
Researcher
Outcome results
None listed